Endocrine Society champions resolution passed by House of Delegates On June 10, the American Medical Association (AMA) House of Delegates passed the Endocrine Society’s resolution to improve access to anti-obesity medications. In the resolution, the AMA committed to advocating for reducing the burden of prior authorization, when healthcare providers must seek insurance plan approval before...
Endocrine News talks with the chair and presenters of “Bariatric Surgery and Emerging Medications: Redefining Roles and Mechanisms,”an ENDO 2025 session that analyzes a variety of factors that are impacted by bariatric surgery including postsurgical hypoglycemia, surgery versus pharmacological solutions, as well as a number of molecular mechanisms of the surgery itself. With so many...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist On June 2, Regeneron Pharmaceuticals, Inc., announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited (“Hansoh”) to acquire exclusive clinical development and commercial rights outside of the...
The Endocrine Society today endorsed the introduction of the bipartisan Treat and Reduce Obesity Act (TROA) in the Senate. The legislation will ensure that Medicare and Medicaid beneficiaries have access to effective anti-obesity medications. Medicare coverage of anti-obesity medications is currently prohibited under law. Access to these medications would benefit millions of Americans. More than...
As I come to the end of my term at ENDO 2025 next month in San Francisco, Calif., I can look back with great pride at what the Endocrine Society has accomplished over the past 12 months. My experience as your president also has reaffirmed my belief that belonging to a strong community is crucial...
Q&A with JoAnn Manson, MD, DrPH, MACP Endocrine News talks to the Endocrine Society’s 2025 Outstanding Clinical Investigator Laureate JoAnn Manson, MD, DrPH, MACP, about her ongoing research on menopausal estrogen therapy, the risks and benefits of nutritional supplements, her numerous large-scale prevention trials, and why she feels that the concept of a “healthspan” is...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome On May 12, Amylyx Pharmaceuticals, Inc. announced positive Week 48 data from the Phase 2 open-label HELIOS clinical trial of AMX0035 (sodium phenylbutyrate [PB] and...
Three Studies Reveal New Insights into Osteoporosis and Bone Health A trio of studies from the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism examines several issues relating to bone health complications. These papers looked at treatment options to increase bone density in breast cancer patients; the impact of sleeve gastrectomy procedures on bone mass...
As I come to the end of my term at ENDO 2025 next month in San Francisco, Calif., I can look back with great pride at what the Endocrine Society has accomplished over the past 12 months. My experience as your president also has reaffirmed my belief that belonging to a strong community is crucial...